Introduction {#Sec1}
============

Intrahepatic cholangiocarcinoma (IHCC) is a highly malignant neoplasm originating from the bile duct system with markers of cholangiocyte differentiation.[@CR1],[@CR2] The incidence of IHCC is increasing worldwide, and it is the second most common form of primary liver cancer next to that of hepatocellular carcinoma. Despite advances in diagnosis and treatment, most patients present with advanced metastatic lesions and are not amenable to surgical extirpation or liver transplantation.[@CR3]--[@CR7] Furthermore, the current chemotherapy regimen that is used to treat IHCC offers very limited benefit in terms of patient survival. When compared with other malignancies, IHCC is generally characterized by strong proliferation, invasion, and early metastasis.

Matrix metalloproteinases (MMPs) are zinc-dependent neutral endopeptidases, which participate in degradation of extracellular matrix proteins.[@CR8],[@CR9] They play roles in many physiological processes, such as bone remodeling and organogenesis, and have additional roles in the reorganization of tissues during pathological conditions such as inflammation, invasion, and metastasis of cancer cells.[@CR8],[@CR10] Many recent studies have provided evidence that the biological activities of various cell surface molecules are proteolytically modulated by several MMPs, including MMP-2, -9, and -7.[@CR11]--[@CR13] These MMPs are likely to regulate cellular functions by activating, inactivating, or releasing membrane proteins. Such regulation of cell surface proteins, as well as MMP-catalyzed degradation of the extracellular matrix (ECM), a natural barrier against tumor invasion, is important to tumor invasion and metastasis.

MMP-7, the smallest of the MMPs, has broad substrate specificity and has been demonstrated to degrade or process a variety of matrix and non-matrix molecules.[@CR14] Unlike most MMPs, which are expressed by stromal cells, MMP-7 is principally expressed by epithelial cells.[@CR15] In human cholangiocarcinomas, this enzyme appears to be one of the most important MMPs because the expression of MMP-7 correlates highly with the malignant and metastatic potentials of the cancers.[@CR16]

In this study, we investigated the association of clinicopathological characteristics of resected IHCCs with prognosis. To improve the prognosis in IHCC, we believe that a fuller, more detailed understanding of the prognostic factors of IHCC is required.

Patients and Methods {#Sec2}
====================

Patients {#Sec3}
--------

From 1996 to 2006, a total of 35 Japanese patients with IHCC underwent hepatectomies at the Department of Surgery I, Oita University Faculty of Medicine, Oita, Japan (Table [1](#Tab1){ref-type="table"}). IHCC was defined as a malignancy arising from the intrahepatic bile duct; perihilar tumors were excluded. Patient age was 65 ± 10 years (mean±SD), and the patients included 9 women and 26 men with a female-to-male ratio of 1:2.9. All patients underwent surgery in our institution. The surgical methods used were right trisectionectomy (*n* = 1), right hepatectomy including extended right hepatectomy (*n* = 12), left hepatectomy including extended left hepatectomy (*n* = 18), and others (*n* = 4). Clinical characteristics and histopathological and immunohistochemical findings of the IHCC patients were examined retrospectively. We followed the guidelines of the ethical principles of the World Medical Association's Declaration of Helsinki in this study.Table 1Patient characteristicsNumber of patients35Age (years)64.9 ± 10.3Sex (male/female)26/9Operative procedure Right trisectionectomy1 Right hepatectomy12 Left hepatectomy18 Others4Operation time (min)463 ± 170Blood loss (g)1,190 ± 750Transfusion17 (48.6%)Tumor size (mm)58.9 ± 31.2Surgical margin (mm)5.6 ± 7.1Complications16 (45.7%)Postoperative hospital stay (days)40.2 ± 21.6

Histopathological Assessment {#Sec4}
----------------------------

Tumor staging and histological classification were assessed according to the TNM Classification of Malignant Tumours defined by the International Union Against cancer. According to the General Rules for the Clinical and Pathological Study of Primary Liver Cancer,[@CR17] macroscopic types of IHCC were classified into two groups: the mass-forming type and other types, which include the periductal and the intraductal growth types. Data for other clinicopathological factors including age, sex, preoperative serum levels of carcinoembryonic antigen (CEA) and CA19-9, operation time, blood loss, transfusion, tumor size, differentiation, lymph node metastasis, invasion of portal and hepatic vein, bile duct invasion, surgical margin, intrahepatic metastasis, and UICC stage were categorized as shown in Table [2](#Tab2){ref-type="table"}.Table 2Results of univariate analysisFactorsPopulation*P* valueAge0.9342 \<65 years old16 (45.7%) ≥65 years old19 (54.3%)Sex0.2666 Male26 (74.3%) Female9 (25.7%)CEA0.0005 \<5 ng/mL27 (77.1%) ≥5 ng/mL8 (22.9%)CA19-90.0002 \<100 U/mL21 (60%) ≥100 U/mL14 (40%)Operative procedure0.8683 \<Right hepatectomy22 (64.7%) ≥Right hepatectomy13 (35.3%)Operation time0.0756 \<400 min16 (45.7%) ≥400 min19 (54.3%)Blood loss0.2382 \<1,000 g18 (51.4%) ≥1,000 g17 (48.6%)Transfusion0.0259 Yes17 (48.6%) No18 (51.4%)Tumor size (mm)0.0034 \<50 mm17 (48.6%) ≥50 mm18 (51.4%)Surgical margin0.0057 Negative31 (88.6%) Positive4 (11.4%)Complications0.7916 Yes16 (45.7%) No19 (54.3%)Macroscopic type0.6720 Mass forming28 (80%) Non-mass forming7 (20%)Differentiation0.3813 Well to moderate22 (62.9%) Poor13 (37.1%)Lymph node metastasis0.0001 Negative25 (71.4%) Positive10 (28.6%)Invasion of portal vein0.0072 Negative20 (57.1%) Positive15 (42.9%)Invasion of hepatic vein0.0067 Negative25 (71.4%) Positive10 (28.6%)Bile duct invasion0.7648 Negative15 (45.5%) Positive18 (54.6%)Intrahepatic metastasis0.0001 Negative21 (60%) Positive14 (40%)UICC stage0.0038 Stage I/II13 (37.1%) Stage III/IV22 (62.9%)MMP-20.4572 Negative23 (65.7%) Positive12 (34.3%)MMP-70.0003 Negative15 (42.9%) Positive20 (57.1%)MMP-90.7037 Negative22 (62.9%) Positive13 (37.1%)VEGF0.5667 Negative19 (57.6%) Positive14 (42.4%)EGFR0.1450 Negative26 (74.3%) Positive9 (25.7%)

Immunohistochemistry {#Sec5}
--------------------

Immunohistochemistry for MMP-2, -7, -9, vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) was performed using an Envision+system (Dako, Cytomation, Glostrup, Denmark). Sources and dilutions of primary antibodies were as follows: anti MMP-2, -7, -9 (mouse monoclonal; diluted 1:100; Daiichi Fine Chemical Co., Ltd., Toyama, Japan), anti-VEGF (mouse monoclonal; diluted 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and anti-EGFR (mouse monoclonal, diluted 1:500; Santa Cruz Biotechnology, Inc.).

Formalin-fixed, paraffin-embedded serial tissue sections (4 μm) were deparaffinized and rehydrated in xylene and grade-diluted ethanol (50--100%) and submerged for 20 min in 0.3% H~2~O~2~ with absolute methanol to block endogenous peroxidase activity. After protein blocking, the sections were incubated with each primary antibody at room temperature for 2 h. The sections were then treated for 20 min with biotinylated anti-mouse IgG (Nichirei Biosciences Inc., Tokyo, Japan), followed by treatment for 30 min with streptavidin--biotin--peroxidase complex (Nichirei Biosciences Inc.), at room temperature with a PBS wash between each step. The slides were developed with diaminobenzidine-H~2~O~2~ (DAB+system, Dako Japan Inc., Tokyo, Japan). The nuclei were also lightly stained with hematoxylin.

Evaluation of Immunohistochemistry {#Sec6}
----------------------------------

The slides were reviewed by two independent observers who had no knowledge of patient outcomes. The expression of MMPs was evaluated semiquantitatively according to the percentage of positively stained cells: negative (positive tumor cells/total tumor cells ≤10%) and positive (positive tumor cells/total tumor cells \>10%). The expression of MMPs in the stromal and inflammatory cells was not evaluated in this study. The expression of VEGF was defined as follows: negative (positive tumor cells/total tumor cells ≤30%) and positive (positive tumor cells/total tumor cells \>30%). The expression of EGFR was defined as follows: negative (positive tumor cells/total tumor cells ≤10%) and positive (positive tumor cells/total tumor cells \>10%).

Statistical Analysis {#Sec7}
--------------------

Results are expressed as means ± SD. Postoperative survival probabilities were calculated by the Kaplan--Meier method and analyzed by the log-rank test. Difference was regarded as significant when the *P* value was less than 0.05. Multivariate analyses were performed using the factors identified as significant by univariate analyses. All statistical analyses were performed using Dr SPSS II software (version 11.01 J; SPSS Japan Inc., Tokyo, Japan).

Results {#Sec8}
=======

Overall Survival and Results of Univariate Analysis {#Sec9}
---------------------------------------------------

Overall 2- and 5-year survival rates were 50.1% and 43.3%, respectively (Fig. [1](#Fig1){ref-type="fig"}). Results of the univariate analysis of prognostic factors for overall survival are listed in Table [2](#Tab2){ref-type="table"}. The univariate analysis revealed the statistically significant prognostic factors among the clinicopathological characteristics to be preoperative serum levels of CEA and CA19-9, intraoperative transfusion, tumor size, surgical margin, lymph node metastasis, invasion of portal and hepatic veins, intrahepatic metastasis, and UICC stage.Fig. 1Cumulative survival curves in 35 patients with resected IHCC. Survival rates at 2 and 5 years after operation were 50.1% and 43.3%, respectively

Immunohistochemical results of expression rates of MMP-2, -7, -9; VEGF; and EGFR and the univariate analysis of prognostic factors for overall survival are also listed in Table [2](#Tab2){ref-type="table"}. MMP-2, -7, -9, VEGF, and EGFR were expressed in 23 (65.7%), 15 (42.9%), 22 (62.9%), 19 (57.6%), and 26 (74.3%) of the 35 IHCC patients, respectively. Univariate analysis revealed the statistically significant prognostic factor among immunohistochemical findings to be MMP-7. The 5-year survival rates of MMP-7(+) and MMP-7(−) patients were 72.7% and 18.3%, respectively (Fig. [2a](#Fig2){ref-type="fig"}). Positively stained cancer cells were distributed heterogeneously in the tumor nests. Carcinoma cell cytoplasm was stained brown for MMP-7, but stromal cells (other than some monocytes or surrounding normal mucosa) were not stained (Fig. [2b, c](#Fig2){ref-type="fig"})Fig. 2**a** Cumulative survival curves in IHCC patients with or without expression of matrix metalloproteinase-7 (MMP-7). The 5-year survival rates of the patients with and without the expression of MMP-7 were 72.7% and 18.3%, respectively. The log-rank test revealed statistically significant differences between the two groups (*P* = 0.0003). Immunostaining for MMP-7 in tumor tissues: **b** positive and **c** negative staining in cancer cells. In the positive staining, cytoplasm of the cancer cells was stained brown for MMP-7, but stromal cells were not stained

Results of Multivariate Analysis {#Sec10}
--------------------------------

In this study, 12 factors including MMP-7 expression were identified as significant prognostic factors by univariate analysis. Multivariate analysis, using these 12 factors, revealed that MMP-7 expression was an independent prognostic factor (hazard ratio \[HR\], 4.698; 95% confidence interval \[CI\], 0.057--0.866; *P* = 0.03) along with intrahepatic metastasis (HR, 5.694; 95% CI, 0.029--0.706; *P* = 0.017; Table [3](#Tab3){ref-type="table"}). Lymph node metastasis showed a tendency to indicate poor prognosis; however, it was not a statistically significant indicator (HR, 3.426; 95% CI, 0.086--1.073; *P* = 0.064).Table 3Results of multivariate analyses regarding overall survivalHR95% CI*P* valueCEA0.0010.242--4.2990.978CA19-91.2700.182--1.5830.260Transfusion1.1840.211--1.5230.271Tumor size (\<50, ≥50 mm)0.3640.57--1.8660.546Surgical margin1.1160.45--14.3840.291Lymph node metastasis3.4260.086--1.0730.064Invasion of portal vein0.4220.12--2.90.516Invasion of hepatic vein0.0180.292--4.1030.894Intrahepatic metastasis5.6940.029--0.7060.017UICC stage0.0060.175--6.5940.938MMP-74.6980.057--0.8660.030

Discussion {#Sec11}
==========

Many clinicopathological factors, such as lymph node metastasis, UICC stage, surgical margin, R0 resection, cirrhosis, use of postoperative adjuvant chemotherapy, and other factors, are potential prognostic factors after resection of IHCC.[@CR18]--[@CR21] However, there has been no definitive way to predict prognosis of IHCC using molecules. This study was performed to determine whether expression of MMP-2, -7, -9, VEGF, and EGFR in resected specimens of IHCC can predict disease outcome. As a result, MMP-7 expression in the tumor cells was found to be a prognostic factor, in addition to that of intrahepatic metastasis.

Recently, many targeted therapies against EGFR, VEGF, and human EGFR type 2 (HER2) such as cetuximab, lapatinib, erlotinib, and bevacizumab have been used for treatment of gastrointestinal cancers. Development of targeted agents in biliary tract cancer (BTC) including IHCC has lagged behind other types of tumors, and there are a few phase II studies examining early experience of efficacy and safety of targeted therapies for BTC patients.[@CR22]--[@CR26] Chemotherapy has been the main therapeutic modality in locally advanced or metastatic BTC, and a randomized, controlled, phase III trial of 410 patients with BTCs has established the combination of gemcitabine and cisplatin as a new global standard for the treatment of locally advanced or metastatic BTC.[@CR27] Although the results are encouraging, the study strongly suggests that BTC remains very difficult to treat with current methods, and molecular targeted therapy is urgently needed for this deadly disease. According to phase II studies of the targeted therapies, cetuximab may be useful for BTC when combined with gemcitabine and oxaliplatin. Gruenberger et al.[@CR22] reported that cetuximab plus gemcitabine/oxaliplatin (GEMOX) was well tolerated and had encouraging antitumor activity, leading to resection in one third of patients. These findings warrant further study of cetuximab plus GEMOX in a large randomized trial. In the present study, the rate of positivity for EGFR was 74.3%, and the 5-year survival rates of EGFR(+) and EGFR(−) patients were 45.9% and 33.3%, respectively. Univariate analysis revealed that EGFR(+) patients had a tendency for poor prognosis; however, the difference between EGFR(+) and EGFR(−) patients was not statistically significant (*P* = 0.145).

MMPs can collectively degrade all components of the ECM and play important roles in embryo development, morphogenesis, tissue remodeling, as well as tumor invasion and metastasis.[@CR28],[@CR29] With regard to tumor invasion, the extracellular proteases, especially MMPs, appear to be crucial for this process. In fact, the invasion of cancer cells into nearby stroma, across blood vessel walls, and through normal epithelial cell layers has been shown to be promoted by various MMPs.[@CR28]--[@CR30] Among the MMPs, MMP-7 is well-known for its involvement with many malignant tumors. MMP-7 is associated with malignancies in the colon, pancreas, and biliary tract.[@CR31],[@CR32] By degrading ECM components such as type-IV collagen, fibronectin, and laminin, MMP-7 plays important roles in invasion and metastasis of carcinoma cells.[@CR33] Interestingly, cleavage of cell surface proteins other than ECM components by this MMP may also contribute to tumorigenic effects. For example, MMP-7 activates EGFR by releasing a ligand of epidermal growth factor and tumor growth factor-α.[@CR34] Moreover, by processing E-cadherin and thereby inducing loose and then tight aggregation of tumor cells, this proteinase induces homotypic adhesion of human colorectal cancer cells and enhances the metastatic potential in vivo.[@CR35] By disrupting tight junction structure and a consequent induction of cell dissociation, MMP-7 might enhance metastasis as well as invasion of IHCC cells.[@CR36]

Some in vitro and in vivo studies have been performed to determine how MMPs contribute to progression of BTC including IHCC. It has been reported that the serum level of MMP-7 is elevated in BTC patients, and this appears to have a potential to differentiate BTC from benign biliary tract diseases.[@CR37],[@CR38] Moreover, histological expression of MMP-7 has been reported to be an unfavorable postoperative prognostic factor of BTC.[@CR39],[@CR40] Also, higher expression of MMP-9 is suggested to be associated with the potential of invasion[@CR41]; however, MMP-9 has not been reported to be a prognostic factor. With regard to MMP-2, it is controversial whether this MMP is associated with poor prognosis.[@CR41],[@CR42] The multivariate analysis in the present study showed that immunohistochemical expression of MMP-7 in IHCC tissues was associated with poor prognosis, and expression of MMP-2 and -9 was not associated with it. This is the first report, to our knowledge, in which multivariate analysis shows the clinical significance of MMP-7 expression in patients with IHCC. In this study, the Kaplan--Meier life table indicated that 5-year survival was 4 times greater in patients without MMP-7-expressing tumors compared with that in patients with MMP-7-expressing tumors (72.7% vs. 18.3%). Therefore, we believe that patients with MMP-7 expressing tumors of IHCC will have poorer prognoses and should be followed up more closely after the operation. In addition, MMP-7 could be a potential therapeutic target. If specific inhibitor of MMP-7 expression by small RNA and so on is developed in the future,[@CR43] it may be useful to improve the prognosis in combination with standard chemotherapy.

In conclusion, the present study suggested that MMP-7 is associated with a poor prognosis in IHCC patients. However, this study included a small number of patients, and further studies enrolling a larger number of patients will be required to confirm the results of this study.
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